Supporters tell finance committee Hawaii should prepare for psychedelic-assisted therapies

Supporters of SB 3199 told the House Finance Committee the state should prepare now for the clinical possibility that MDMA- and psilocybin-assisted therapies could gain federal approval and clinical use. Witnesses included psychiatrists, researchers and multiple veterans who described treatment-resistant PTSD or depression and said existing services had not been sufficient.

Dr. Robin Martin, a Hawaii psychiatrist, described a patient who had exhausted conventional treatments and said the state should not wait to build safe pathways: "Cases like this are not rare... I can't help but wonder if he might still be alive if more treatment options were accessible to him." Jesse McGlaughlin of Reason for Hope and other advocacy groups framed the proposal as a measured, public-health oriented step: SB 3199 would create a task force to prepare regulatory, clinical and workforce infrastructure should federal approvals permit clinical deployment.

Veterans and military spouses repeatedly testified that they or family members had traveled off-island to obtain psychedelic-assisted treatments and asked the state to build the governance, training and oversight structures needed for safe local access. Researchers on the call described existing evidence and cited the FDA’s “breakthrough therapy” designations for some psychedelic compounds as a reason to plan now.

Opposition and caution were limited in the hearing; concerns raised by a few commenters centered on ensuring careful training standards, safeguarding clinical oversight, and avoiding premature deployment without clear evidence. The committee took testimony and recessed for other items; SB 3199 supporters urged lawmakers to adopt the task force as a prudent regulatory and workforce planning step.